Nyxoah (NASDAQ:NYXH) Stock Rating Reaffirmed by HC Wainwright

Nyxoah (NASDAQ:NYXH)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a note issued to investors on Monday, Benzinga reports. They currently have a $18.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 96.08% from the stock’s previous close.

Several other research firms have also recently issued reports on NYXH. Cantor Fitzgerald decreased their price target on Nyxoah from $17.00 to $16.00 and set an “overweight” rating for the company in a research note on Wednesday, August 7th. Stifel Nicolaus lowered their target price on shares of Nyxoah from $27.00 to $19.00 and set a “buy” rating on the stock in a research note on Monday, June 24th. Finally, Oppenheimer reduced their price target on shares of Nyxoah from $15.00 to $13.00 and set an “outperform” rating for the company in a research note on Wednesday, August 7th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, Nyxoah has a consensus rating of “Buy” and a consensus price target of $17.20.

Nyxoah Trading Down 3.9 %

Nyxoah stock opened at $9.18 on Monday. The firm has a 50-day moving average price of $8.24 and a two-hundred day moving average price of $9.34. Nyxoah has a 52-week low of $4.00 and a 52-week high of $20.00. The firm has a market capitalization of $228.95 million, a price-to-earnings ratio of -5.60 and a beta of 1.43. The company has a quick ratio of 5.16, a current ratio of 5.47 and a debt-to-equity ratio of 0.09.

Nyxoah (NASDAQ:NYXH) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.01). Nyxoah had a negative return on equity of 42.00% and a negative net margin of 908.32%. The business had revenue of $0.83 million for the quarter, compared to analyst estimates of $1.93 million. Sell-side analysts expect that Nyxoah will post -1.91 earnings per share for the current year.

Institutional Investors Weigh In On Nyxoah

Several hedge funds and other institutional investors have recently bought and sold shares of NYXH. CVI Holdings LLC bought a new position in shares of Nyxoah during the 2nd quarter valued at about $1,292,000. Ikarian Capital LLC bought a new stake in Nyxoah during the first quarter worth approximately $684,000. Finally, Iron Triangle Partners LP acquired a new position in Nyxoah in the first quarter worth approximately $3,413,000.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.